Affinergy, a developer of stents that also include medication, will be among the companies making presentations at “Convergence: The Drug/Device Summit”.

The event is set for March 21-23 in Pittsburgh. Some 50 companies were selected.

Affinergy, which also updated its web site recently, utilizes technology licensed from Duke University to combine medical devices such as stents and a therapeutic agent.

The company is involved in a number of preclinical programs.

“The convergence of drugs and devices is fundamentally enabled by our core competency, mediating adhesion of biologicals and localizing delivery of therapeutic agents,” said Peyton Anderson, chief executive officer of Affinergy.